Mersana Therapeutics Appoints Tushar Misra as Chief Manufacturing Officer
indianewengland.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from indianewengland.com Daily Mail and Mail on Sunday newspapers.
Mersana Therapeutics Announces Appointment of Tushar Misra, Ph D , as Chief Manufacturing Officer
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Mersana Therapeutics Announces Appointment of Alejandra Carvajal as Senior Vice President and Chief Legal Officer
April 26, 2021 08:00 ET | Source: Mersana Therapeutics, Inc. Mersana Therapeutics, Inc. Cambridge, Massachusetts, UNITED STATES
CAMBRIDGE, Mass., April 26, 2021 (GLOBE NEWSWIRE) Mersana Therapeutics, Inc. (Nasdaq: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced the appointment of Alejandra Carvajal as Senior Vice President and Chief Legal Officer.
“With our UPLIFT strategy now underway for UpRi and our growing pipeline of product candidates derived from our innovative ADC platforms, we are thrilled to have Alejandra join the team at this time of immense growth,” said Anna Protopapas, President and Chief Executive Officer of Mersana Therapeutics. “Alejand
Mersana Therapeutics Presents Preclinical Data Highlighting Potential of XMT-2056 and XMT-1660 in Three Posters at Virtual 2021 AACR Annual Meeting
April 10, 2021 09:00 ET | Source: Mersana Therapeutics, Inc. Mersana Therapeutics, Inc. Cambridge, Massachusetts, UNITED STATES
CAMBRIDGE, Mass., April 10, 2021 (GLOBE NEWSWIRE) Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today presented preclinical data from XMT-1660, a B7-H4-targeted Dolasynthen antibody-drug conjugate (ADC), and XMT-2056, an Immunosynthen-based STING-agonist ADC at the Virtual 2021 American Association for Cancer Research Annual Meeting being held from April 10-15th.